We are live on ! Find out more

974 hedge funds and large institutions have $47.5B invested in DexCom in 2023 Q4 according to their latest regulatory filings, with 195 funds opening new positions, 326 increasing their positions, 358 reducing their positions, and 114 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 195 | Existing positions closed: 114

47% more funds holding in top 10

Funds holding in top 10: 1725 (+8)

38% more capital invested

Capital invested by funds: $34.4B → $47.5B (+$13.2B)

8% more funds holding

Funds holding: 903974 (+71)

4.32% more ownership

Funds ownership: 94.93%99.24% (+4.3%)

9% less repeat investments, than reductions

Existing positions increased: 326 | Existing positions reduced: 358

22% less call options, than puts

Call options by funds: $824M | Put options by funds: $1.05B

Holders
974
Holders Change
+71
Holders Change %
+7.86%
% of All Funds
14.2%
Holding in Top 10
25
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+47.06%
% of All Funds
0.36%
New
195
Increased
326
Reduced
358
Closed
114
Calls
$824M
Puts
$1.05B
Net Calls
-$228M
Net Calls Change
-$149M

DXCM Hedge Fund Activity: Q4 2023 in Review

974 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q4 2023, worth a combined $47.5B — up 38% from $34.4B a quarter earlier.

Buyers outnumbered sellers: 195 funds opened new DXCM positions and 114 closed out — a net gain of 81 holders — while 326 added to existing stakes and 358 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $590M. The largest seller was Jennison Associates, cutting an estimated $400M.

  • 974 institutional investors held DexCom (DXCM) as of Q4 2023, up from 903 in Q3 2023.
  • Funds reported $47.5B of DexCom stock for Q4 2023, up 38% quarter-over-quarter.
  • 195 funds opened new DexCom positions in Q4 2023 and 114 closed out, a net change of +81 holders.
  • The largest DexCom buyer in Q4 2023 was Morgan Stanley, an estimated $590M added.
  • The largest DexCom seller in Q4 2023 was Jennison Associates, an estimated $400M sold.

Based on aggregated 13F filings for Q4 2023.